Price
$12.84+23.34%Social Signal Score
Analyst Ratings
36 analystsRevenue
$1.02B-24.51%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Albert A. Manzone
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 8,100
- Beta
- 0.54
- Country
- IE
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- -0.37
Financials
Revenue
$1.02B-24.5%Net Income
$74.50MEBITDA
$143.80M-46.2%Free Cash Flow
$124.00M-55.1%EPS (diluted)
$0.53Shares Outstanding (diluted)
139.60M-2.6%Operating Expenses
$253.20MCash & Debt
$399.70MReturn of Capital
$80.10MRevenue by Segment (annual)
$4.25BDividend per Share
$0.29Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $4.25B | $-1.43B | $-10.29 |
| 2024 | $4.37B | $-171.80M | $-1.25 |
| 2023 | $4.66B | $-12.70M | $-0.09 |
| 2022 | $4.45B | $-140.60M | $-0.97 |
| 2021 | $4.14B | $-68.90M | $-0.98 |
| 2020 | $4.09B | $-162.60M | $-1.19 |
| 2019 | $3.87B | $146.10M | $1.07 |
| 2018 | $4.73B | $131.00M | $0.95 |
| 2017 | $4.95B | $119.60M | $0.84 |
| 2016 | $5.28B | $-4.01B | $-28.01 |
| 2015 | $4.60B | $127.90M | $0.92 |
| 2014 | $4.06B | $205.30M | $1.78 |
| 2013 | $3.54B | $441.90M | $4.71 |
| 2012 | $3.17B | $401.61M | $4.31 |
Valuation
PRGOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
140+154.55%Social Signal Score
Mentions (8)
- Newszacks.com·11d ago·Neutral
Perrigo (PRGO) Moves 6.1% Higher: Will This Strength Last? Perrigo (PRGO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
View source ↗ - Newsdefenseworld.net·11d ago·Negative
Squarepoint Ops LLC Cuts Position in Perrigo Company plc $PRGO Squarepoint Ops LLC reduced its stake in shares of Perrigo Company plc (NYSE: PRGO) by 95.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,900 shares of the company's stock after selling 443,842 shares during the quarter.
View source ↗ - Newszacks.com·31d ago·Neutral
Perrigo (PRGO) Up 13.8% Since Last Earnings Report: Can It Continue? Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newsprnewswire.com·40d ago·Neutral
Perrigo to Attend the Barclays Global Consumer Conference DUBLIN, Aug. 27, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of consumer self-care products, today announced that Interim President and CEO Albert Manzone and CFO Eduardo Bezerra are scheduled to participate in investor meetings at the Barclays Global Consumer Conference on Thursday, September 10th, 2026. About Perrigo Perrigo Company plc is a leading pure-play self-care company with over a century of exp…
View source ↗ - Newszacks.com·40d ago·Negative
PRGO or NEOG: Which Is the Better Value Stock Right Now? Investors with an interest in Medical - Products stocks have likely encountered both Perrigo (PRGO) and Neogen (NEOG). But which of these two stocks is more attractive to value investors?
View source ↗ - Newsseekingalpha.com·54d ago·Positive
Perrigo: The Rebound Is Just Getting Started Perrigo Company remains substantially undervalued, with a Buy rating justified by strong income and growth potential. Recent quarterly EPS and revenue beats, coupled with market share gains, signal improving fundamentals despite a soft OTC market. Management's focus on cost control, debt reduction, and dividend growth underpins a compelling 16–21% expected annual total return.
View source ↗ - Newszacks.com·56d ago·Positive
PRGO vs. NEOG: Which Stock Is the Better Value Option? Investors with an interest in Medical - Products stocks have likely encountered both Perrigo (PRGO) and Neogen (NEOG). But which of these two companies is the best option for those looking for undervalued stocks?
View source ↗ - Newsmarketbeat.com·58d ago·Neutral
Perrigo Q2 Earnings Call Highlights Perrigo NYSE: PRGO reported second-quarter 2026 results that exceeded its internal earnings expectations, while sales declined amid soft consumer self-care categories, retailer inventory reductions and a slower start to seasonal demand. The company maintained its full-year outlook, citing improving category trends, market-share gains and expected second-half contributions from innovation, distribution and demand-generation efforts.
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $0.52 per share
Typical surprise +6.7% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$0.50 vs $0.39beat
- Wed, May 6$0.43 vs $0.39beat
- Thu, Feb 26$0.77 vs $0.80miss
- Wed, Nov 5$0.80 vs $0.75beat
- Wed, Aug 6$0.57 vs $0.59miss
- Wed, May 7$0.60 vs $0.56beat
Estimates and results for PRGO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PRGO officers and directors.
No open-market trades in the recent filings. All 100 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
100 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Michael T. McCaulhouse · TX10 · disclosed Jul 19, 2023 (26d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Jul 19, 2023 (23d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Jul 19, 2023 (48d later)Sell$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Jul 19, 2023 (20d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Jul 19, 2023 (27d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Jul 19, 2023 (23d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Jul 19, 2023 (27d later)Sell$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Jul 19, 2023 (20d later)Sell$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Jul 19, 2023 (21d later)Sell$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Jul 19, 2023 (47d later)Sell$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Jul 19, 2023 (44d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Jul 19, 2023 (44d later)Sell$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Jul 19, 2023 (26d later)Sell$50,001 - $100,000
- Michael T. McCaulhouse · TX10 · disclosed Jul 19, 2023 (47d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Jul 19, 2023 (48d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Jul 19, 2023 (21d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Jun 22, 2023 (36d later)Sell$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Jun 22, 2023 (41d later)Sell$100,001 - $250,000
- Michael T. McCaulhouse · TX10 · disclosed Jun 22, 2023 (36d later)Sell$50,001 - $100,000
- Michael T. McCaulhouse · TX10 · disclosed Jun 22, 2023 (35d later)Sell$15,001 - $50,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.